Innovation Hub Opens: BioBAY Phase III B Welcomes 21 Pioneering Biotech Companies

Today (July 18), Phase III, Zone B of the Suzhou BioBAY Industrial Park was officially opened, welcoming its first batch of 21 new tenant companies. As the ocean accepts all rivers and the Qilin Pavilion gathers many talents, BioBAY has continuously optimized its space supply and enhanced its diversified service functions, attracting leading enterprises and top-tier talent in the biopharmaceutical and life sciences sectors. These efforts contribute to building a vibrant innovation cluster for the biopharmaceutical industry and support the rapid development of Suzhou Industrial Park’s “Priority Industry.”

The Phase III, Zone B project of BioBAY is located at No. 99 Jingu Road, Suzhou Industrial Park. Covering an area of 3.11 hectares with a total gross floor area of 70,500 square meters, the facility currently hosts 21 companies with a total investment of RMB 5 billion. It is committed to establishing an industrialization base for nucleic acid drugs, gene therapy, and high-end medical devices. This “grand opening” not only meets the practical needs of industrial development but also represents another instance of the park’s “forward-looking planning” in building industrial infrastructure. It aims to help the park further develop a complete chain for biopharmaceutical incubation, acceleration, and industrialization, support the construction of the National Center for Biopharmaceutical Technology Innovation, and promote higher-quality industrial development.

Notably, the first batch of 21 companies to settle in includes Shengyin Biologics, Dianjing Biologics, Maohang Biologics, Viscera Health, Insilico Medicine, Xingrui Pharma, StarrySky Medical, Xuanren Technology, Innovent Biologics, Xinjing Zhiyuan, Synaffix, Shutong Medical, Duality Biologics, Shize Biologics, Puluo Medical, Guangjing Biologics, Haimai Medical, Unknowns (Weizhijun), Jinshi Technology, Yuanqi Biologics, and Kaiji Biologics. These companies focus on international frontiers such as AI-driven drug discovery, cell therapy, nucleic acid therapeutics, novel antibodies and in vitro diagnostics, and high-end medical devices—all key strategic areas for BioBAY’s future development. Their presence will inject new momentum into the biopharmaceutical industry both within the park and across China.

In the field of AI-driven drug discovery,Insilico MedicineA pioneer and leader in this niche sector. The company has currently built three highly efficient AI-driven drug discovery platforms, focusing on and spanning the three major stages of new drug development: a novel target discovery platform, a compound design and generation platform, and a clinical trial prediction platform. These platforms are advancing the R&D of innovative drugs in areas such as cancer, fibrosis, infectious diseases, and neurodegenerative disorders. Since its establishment in 2014, Insilico Medicine has secured over USD 300 million in financing and entered into strategic collaborations with more than 30 pharmaceutical R&D companies across the United States, Europe, China, Japan, and other countries and regions. Meanwhile, it has launched multiple internal R&D pipelines targeting novel targets, difficult-to-drug targets, and undruggable targets. With its presence in BioBAY, Insilico Medicine will establish an R&D center in Suzhou to build an automated AI-driven drug discovery platform.

In the field of cell therapy,Shize BiotechCommitted to providing scalable, low-cost stem cell therapy solutions for major diseases lacking clinical cures, such as Parkinson’s disease. The company has established a clinical-grade cell quality testing system, along with key platforms for pluripotent stem cell reprogramming, cell process development, immunological analysis, and in vitro efficacy evaluation, which can be leveraged to develop treatments for a range of major degenerative diseases. Notably, ICell Therapeutics has garnered favor from top-tier investment institutions, completing tens of millions of RMB in angel financing and nearly 100 million RMB in Pre-A financing, with participation from Lilly Asia Ventures, Qiming Venture Partners, and other firms.

In the field of nucleic acid therapeutics, co-founded by Dr. Wang Weimin and Dr. Wang Shiyu, leading figures in the nucleic acid drug industry,Shengyin BiotechIt is a biotechnology company focused on the research, development, and commercialization of RNAi therapeutics. The company has established a pipeline of eight preclinical candidates spanning metabolic diseases, central nervous system disorders, retinal diseases, immunology, and oncology. Its most advanced candidate is expected to file an Investigational New Drug (IND) application by mid-2023. To date, the company has completed $52 million in financing, with support from investors including Hillhouse Capital, Qiming Venture Partners, and Taifu Capital.

In the field of novel antibodies,Duality BiologicsIt is a biotechnology company dedicated to the innovative research and development of antibody-drug conjugate (ADC) therapeutics. The company has developed multiple next-generation ADC technology platforms with global independent intellectual property rights, including DITAC, DIMAC, and DISAC. Focusing on oncology and autoimmune diseases, it has established a pipeline of nearly 10 First-in-class and Best-in-class product candidates, several of which have filed Investigational New Drug (IND) applications in both China and the United States and entered clinical trials. To date, the company has raised $120 million in financing.

In the field of in vitro diagnostics,Xingtong MedicalPossessing the only truly independent, innovative, and world-leading immunoassay technology in China. Its core technology is a biosensor called Test-On-A-Probe (TOP), which holds over 50 global patents. This technology enables the integration of different detection methods on a single probe, thereby facilitating the analysis of proteins, antibodies, nucleic acids, small molecules, cells, and more. The proprietary cyclic amplification fluorescence detection technology has secured nearly 30 PCT and Chinese invention patents, representing the only truly independent, innovative, and world-leading immunoassay technology in China. In May 2021, its U.S. parent company, Access Medical Systems, completed a new round of financing exceeding USD 100 million, co-led by Hillhouse Capital and Sequoia Capital.

In the field of high-end medical devices, committed to becoming a world-leading innovative enterprise in transcatheter ultrasound therapyPuluo Medical, establishing three major ultrasound therapeutic platforms—the transcatheter ultrasound ablation platform, the transcatheter ultrasound thrombolysis platform, and the ultrasound-assisted decalcification platform—to achieve precise treatment through flexible therapeutic modalities while avoiding X-ray radiation. Puluo Medical has pioneered an interventional catheter that integrates both ultrasound therapy and ultrasound imaging functions, providing an innovative integrated solution for therapy and imaging. By leveraging the advantages of ultrasound and combining imaging with treatment, this approach eliminates the hazards of X-rays, enhancing safety for both patients and physicians, while enabling real-time monitoring and precise therapeutic outcomes.

Suzhou BioBAY is an innovative technological platform for the development of Suzhou’s biopharmaceutical industry. After fifteen years of dedicated cultivation, it has gathered more than 550 high-tech biopharmaceutical enterprises and 35,000 high-level scientific and technical talents, forming three major industrial clusters focused on innovative drug R&D, high-end medical devices, and biotechnology, with the aim of building a world-class bio-industry ecosystem. In recent years, while consolidating its foundations in small-molecule targeted innovative drugs and antibody therapies, BioBAY has strategically prioritized cell and gene therapies, nucleic acid drug R&D, AI-driven drug discovery, and high-end medical devices as key future directions, continuously attracting top-tier talent and resources to fuel the growth of its “No. 1 Industry.”